US 12,110,324 B2
Antigen binding molecules targeting thymic stromal lymphopoietin (TSLP)
Antonios O. Aliprantis, Natick, MA (US); Zachary Kohl Costello, Cambridge, MA (US); Anthony John Coyle, Boston, MA (US); Kristen Park Hopson, Lincoln, MA (US); Ryan Terrell Phennicie, Andover, MA (US); Alexis Hiram Ramos, Wilbraham, MA (US); Adam Reid Root, Newbury, MA (US); Lana Dinic, Newton, MA (US); and Karin Alma Frieda Reif, San Francisco, CA (US)
Assigned to Flagship Pioneering Innovations VI, LLC, Cambridge, MA (US)
Filed by Flagship Pioneering Innovations VI, LLC, Cambridge, MA (US)
Filed on Jul. 21, 2023, as Appl. No. 18/356,891.
Claims priority of provisional application 63/369,202, filed on Jul. 22, 2022.
Claims priority of provisional application 63/369,152, filed on Jul. 22, 2022.
Claims priority of provisional application 63/369,203, filed on Jul. 22, 2022.
Claims priority of provisional application 63/369,165, filed on Jul. 22, 2022.
Claims priority of provisional application 63/369,175, filed on Jul. 22, 2022.
Claims priority of provisional application 63/369,204, filed on Jul. 22, 2022.
Claims priority of provisional application 63/369,158, filed on Jul. 22, 2022.
Claims priority of provisional application 63/369,206, filed on Jul. 22, 2022.
Prior Publication US 2024/0034780 A1, Feb. 1, 2024
Int. Cl. C07K 16/24 (2006.01); A61P 11/06 (2006.01)
CPC C07K 16/244 (2013.01) [A61P 11/06 (2018.01); C07K 2317/24 (2013.01); C07K 2317/565 (2013.01)] 23 Claims
 
1. An anti-thymic stromal lymphopoietin (TSLP) antibody or antigen-binding fragment thereof comprising:
a) a heavy chain variable domain (VH) that comprises a heavy chain complementarity-determining region (HCDR) 1 comprising the amino acid sequence of SEQ ID NO:31, a HCDR2 comprising the amino acid sequence of SEQ ID NO:35, and a HCDR3 comprising the amino acid sequence of SEQ ID NO:50; and
b) a light chain variable domain (VL) that comprises a light chain complementarity-determining region (LCDR) 1 comprising the amino acid sequence of SEQ ID NO:60, a LCDR2 comprising the amino acid sequence DDS, and a LCDR3 comprising the amino acid sequence of SEQ ID NO:71.